EN DE
Watch Medigen Vaccine Biologics for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medigen Vaccine Biologics (6547) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Medigen Vaccine Biologics stock TWD 34.29, price TWD 51.50, that is 33.4% below the price, quality 41 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006547003

MV Medigen Vaccine Biologics logo Thin data Nov 10, 2026

Medigen Vaccine Biologics

6547 · TWO
Expensive, weak quality

Our calculation puts a fair price 33% below what the stock costs today.

Low debt
Quality 41/100
Expensive Growth (revenue 5y +121.5 %/yr in TWD)
Mixed vs. peers (5/10)
Revenue last quarter 21% below a year ago.
Fair value 34.29 TWD · Overvalued
Loss-making · -29.1% net margin (TTM)
Negative free cash flow
Narrow moat 26/100 · thin data
Thin data
Estimate
Watch Medigen Vaccine Biologics for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

246.60 TWD 33.75 TWD Fair Value 34.29 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 33.75 TWD – 246.60 TWD · fair‑value band 25.72 TWD – 42.86 TWD · the 51.50 TWD price screens above the 34.29 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Medigen Vaccine Biologics in your weekly email

Every Wednesday you see whether Medigen Vaccine Biologics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.

Show moreShow less

It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses.

The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. The company was incorporated in 2012 and is headquartered in Zhubei, Taiwan.

Stock analysis

Medigen Vaccine Biologics (6547) currently trades at 51.50 TWD, while our estimate is 34.29 TWD, 33% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 25.72 TWD (bear) to 42.86 TWD (bull), the price of 51.50 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Medigen Vaccine Biologics reported revenue of 613M TWD in FY2025 versus 3.3B TWD in FY2021, a compound −34.3%/yr. Reported net income was −282M TWD in FY2025.

Key figures

Market cap 16.9B TWD (≈ $516M) Small · P/S ratio 28.5 · EPS (TTM) −0.5100 TWD · Net margin −29.1% · Return on equity −4.6% · Return on assets (EBIT) −4.6% (5-year average) · Operating margin 18.6% · Revenue (TTM) 574M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (low confidence).

What moves the price

The share trades about 24% below its 52-week high and 46% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −33%, 6547 screens richer than that median.

Fair Value

Bear 25.72 TWD Fair Value 34.29 TWD Bull 42.86 TWD
Price 51.50 TWD · Downside -33.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 16
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 88
Debt, balance sheet and risk of trouble
Investment 88
Does it invest with discipline instead of growing at any price?
Low Volatility 61
How calm the share price moves, does not count
Price momentum 66
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 65
Distance to the 52-week high, does not count
New shares 79
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+121.5%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+186.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5,717.1% (2020) → −43.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6547 screens overvalued: fair value 33% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Medigen Vaccine Biologics with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Above median
Fair Value upside −33.4% · Below median
Profitability
Return on assets −7.2% · Above median
Net margin (12 months) −29.1% · Below median
Operating margin (12 months) 18.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −20.6% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.87× · Pricier than median
P/S (12 months) 29.50× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 6547
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 6547
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 6547
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 6547
argenx SE ARGX $971.55 $908.40 −7% vs 6547
CSL Limited CSL A$201.68 A$181.40 −10% vs 6547
Moderna, Inc MRNA $250.83 $158.70 −37% vs 6547
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 6547
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 6547
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 6547

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medigen Vaccine Biologics: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medigen Vaccine Biologics Fair Value". https://www.fairvalue-calculator.com/stock/6547

Frequently asked questions

Is Medigen Vaccine Biologics (6547) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 34.29 TWD versus a price of 51.50 TWD, about 33% lower (overvalued).
What is the fair value of 6547?
Our estimate for Medigen Vaccine Biologics is 34.29 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 51.50 TWD.
What is the quality score of 6547?
Medigen Vaccine Biologics has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medigen Vaccine Biologics (6547)?
Our calculated price target is the estimate of 34.29 TWD (as of Nov 10, 2026). Cautious scenario 25.72 TWD, optimistic scenario 42.86 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Medigen Vaccine Biologics stock forecast for 2026?
Our estimate puts fair value at 34.29 TWD, about 33% lower versus a price of 51.50 TWD (overvalued). Cautious scenario 25.72 TWD, optimistic scenario 42.86 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Medigen Vaccine Biologics (6547)?
Medigen Vaccine Biologics reported trailing-twelve-month revenue of about 574M TWD (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Medigen Vaccine Biologics (6547)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medigen Vaccine Biologics it is 34.29 TWD per share (as of Nov 10, 2026), against a price of 51.50 TWD.
Is Medigen Vaccine Biologics stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 6547 trades above its calculated fair value: price 51.50 TWD, fair value 34.29 TWD, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6547?
No. The price is what the market pays today (51.50 TWD); the fair value is what the company's own numbers justify (34.29 TWD). For Medigen Vaccine Biologics the two are 17.21 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Medigen Vaccine Biologics worth?
The market values Medigen Vaccine Biologics at about 16.9B TWD (market capitalisation, as of Nov 10, 2026). Per share that is 51.50 TWD; our models calculate a fair value of 34.29 TWD per share.
What do the bullish and bearish scenarios say about 6547?
Our models span a range for Medigen Vaccine Biologics: cautious scenario 25.72 TWD, base 34.29 TWD, optimistic 42.86 TWD per share (as of Nov 10, 2026, price 51.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medigen Vaccine Biologics (6547)?
Balance-sheet figures for Medigen Vaccine Biologics (as of Nov 10, 2026): return on equity −4.6%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 6547 from its 52-week high?
Medigen Vaccine Biologics trades at 51.50 TWD, about 24% below its 52-week high of 68.10 TWD and 46% above the low of 35.20 TWD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 34.29 TWD is for.
Which stocks are comparable to Medigen Vaccine Biologics?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medigen Vaccine Biologics stock attractive at the current price?
The data as of Nov 10, 2026: price 51.50 TWD, calculated fair value 34.29 TWD (−33%), Quality Score 41/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Medigen Vaccine Biologics itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medigen Vaccine Biologics (6547)?
The closing price on Nov 10, 2026 was 51.50 TWD. Our estimate is 34.29 TWD, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medigen Vaccine Biologics right now?
The price sits above even our optimistic bull case (42.86 TWD). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Medigen Vaccine Biologics

How large is the market capitalisation of Medigen Vaccine Biologics (6547)?
The market capitalisation of Medigen Vaccine Biologics is 16.9B TWD (≈ $516M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medigen Vaccine Biologics (6547)?
The price-to-sales ratio of Medigen Vaccine Biologics is 28.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medigen Vaccine Biologics (6547)?
Earnings per share at Medigen Vaccine Biologics are −0.5100 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medigen Vaccine Biologics (6547)?
The net margin of Medigen Vaccine Biologics is −29.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medigen Vaccine Biologics (6547)?
The return on equity (ROE) of Medigen Vaccine Biologics is −4.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medigen Vaccine Biologics (6547)?
On an EBIT basis the return on assets of Medigen Vaccine Biologics is −4.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medigen Vaccine Biologics (6547)?
The operating margin of Medigen Vaccine Biologics is 18.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medigen Vaccine Biologics (6547)?
Revenue at Medigen Vaccine Biologics is growing −20.6% versus a year earlier (3y avg +18.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Medigen Vaccine Biologics (6547) generate?
The free cash flow of Medigen Vaccine Biologics is −101M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Medigen Vaccine Biologics (6547) carry?
The net debt of Medigen Vaccine Biologics is 622M TWD (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Medigen Vaccine Biologics in the live analysis

One click puts Medigen Vaccine Biologics on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.